Education
About Us
Working with TipRanks
Follow Us
Hightide Therapeutics Inc (HK:2511)
:2511
RESEARCH TOOLSreports
Total Valuation
Hightide Therapeutics Inc has a market cap or net worth of HK$1.48B. The enterprise value is HK$5.44B.
Market CapHK$1.48B
Enterprise ValueHK$5.44B
Share Statistics
Hightide Therapeutics Inc has 514,770,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding514,770,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Hightide Therapeutics Inc’s return on equity (ROE) is -0.90 and return on invested capital (ROIC) is -88.59%.
Return on Equity (ROE)-0.90
Return on Assets (ROA)-0.68
Return on Invested Capital (ROIC)-88.59%
Return on Capital Employed (ROCE)-0.99
Revenue Per Employee0.00
Profits Per Employee-5.45M
Employee Count70
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Hightide Therapeutics Inc is -1.41. Hightide Therapeutics Inc’s PEG ratio is 0.00.
PE Ratio-1.41
PS Ratio0.00
PB Ratio-19.10
Price to Fair Value1.27
Price to FCF-57.59
Price to Operating Cash Flow-58.71
PEG Ratio0.00
Income Statement
In the last 12 months, Hightide Therapeutics Inc had revenue of 0.00 and earned -381.79K in profits. Earnings per share was -0.84.
Revenue0.00
Gross Profit0.00
Operating Income-444.75K
Pretax Income-381.52K
Net Income-381.79K
EBITDA-444.22K
Earnings Per Share (EPS)-0.84
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Hightide Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.37
52-Week Price Change80.92%
50-Day Moving Average2.42
200-Day Moving Average1.48
Relative Strength Index (RSI)50.42
Average Volume (3m)3.83M
Important Dates
Hightide Therapeutics Inc upcoming earnings date is Mar 28, 2025, TBA Not Confirmed.
Last Earnings DateAug 28, 2024
Next Earnings DateMar 28, 2025
Ex-Dividend Date―
Financial Position
Hightide Therapeutics Inc as a current ratio of 4.67, with Debt / Equity ratio of -372.46%
Current Ratio4.67
Quick Ratio4.67
Debt to Market Cap0.11
Net Debt to EBITDA0.52
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Hightide Therapeutics Inc has paid 269.00 in taxes.
Income Tax269.00
Effective Tax Rate>-0.01
Enterprise Valuation
Hightide Therapeutics Inc EV to EBITDA ratio is -0.69, with an EV/FCF ratio of -1.01.
EV to Sales0.00
EV to EBITDA-0.69
EV to Free Cash Flow-1.01
EV to Operating Cash Flow-1.03
Balance Sheet
Hightide Therapeutics Inc has HK$490.52M in cash and marketable securities with ¥77.91M in debt, giving a net cash position of -HK$412.62M billion.
Cash & Marketable SecuritiesHK$490.52M
Total Debt¥77.91M
Net Cash-HK$412.62M
Net Cash Per Share-HK$0.80
Tangible Book Value Per ShareHK$0.94
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Hightide Therapeutics Inc is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast54.79%